CSACI position statement: transition recommendations on existing epinephrine autoinjectors
Abstract Epinephrine is the first line treatment for anaphylaxis, an acute potentially life-threatening allergic reaction. It is typically administered intramuscularly in the anterolateral thigh at a dose of 0.01 mg/kg of 1:1000 (1 mg/ml) solution to a maximum initial dose of 0.5 mg. Currently in Ca...
Na minha lista:
| Principais autores: | , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BMC
2021-12-01
|
| coleção: | Allergy, Asthma & Clinical Immunology |
| Assuntos: | |
| Acesso em linha: | https://doi.org/10.1186/s13223-021-00634-2 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|